Chinese pharma is about to hit the global market, says a leader of the charge

British-born Christian Hogg can say with some confidence that the milestone of a Chinese company taking a drug candidate from discovery all the way to global registration will be achieved within the next two to three years.

As the chief executive of Hutchison China MediTech Limited, a biopharma which is majority owned by the conglomerate CK Hutchison Holdings (SEHK: 0001) and has a potentially ground-breaking cancer drug poised to enter Phase III testing in the USA with savolitinib, he also has a very real hope that it will be his company which leads the way, Mr Hogg told The Pharma Letter in an exclusive interview.

Having joined the company, which is known as Chi-Med, at its outset in 2000, Mr Hogg has seen the ingredients coming together to put China on the brink of becoming a major player in global pharma.